Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Deferred Tax Liability of $44.7 million for Q4 2025, up 574.8% year-on-year from $6.6 million in Q4 2024, and up 574.8% on a QoQ basis from $6.6 million in Q4 2024.
Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $44.7 million the latest figure, recorded in Q4 2025.
- Quarterly Non-Current Deferred Tax Liability rose 574.8% year-over-year to $44.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $44.7 million (up 574.8% YoY) and the FY2025 annual result came in at $44.7 million, up 671.33% from the prior year.
- Non-Current Deferred Tax Liability advanced to $44.7 million in Q4 2025 per TLX's latest filing, from $6.6 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for TLX reached as high as $44.7 million in Q4 2025 and fell as low as $6.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Telix Pharmaceuticals | 3.55 Bn | 3.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2024 | 6.63 Mn |
| Dec 31, 2024 | 6.63 Mn |